Tag: #pfizer

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi

Pfizer Keeps 2026 Outlook as Q1 Revenue Rises 5%; COVID Sales Slide

Pfizer posted 5% revenue growth in Q1 and kept its 2026 outlook, as gains from newer drugs offset steep declines in Comirnaty and Paxlovid sales.

$PFE, #pfizer, #earnings, #pharma